J&J Hit With $1.75M Verdict In 4th Philly Risperdal Case

Law360, Philadelphia (November 9, 2015, 3:41 PM EST) -- A Johnson & Johnson unit was slapped with a $1.75 million verdict in Pennsylvania state court on Monday in a fourth case alleging the company failed to properly disclose the risks of abnormal breast growth in adolescent boys using the antipsychotic drug Risperdal.

About 1,500 cases over Johnson & Johnson's Risperdal are pending as part of a mass tort docket in Philadelphia County, according to court records. (Credit: AP) The jury agreed that the blockbuster drug was a substantial factor in causing an autistic Maryland boy to grow breasts after he was first prescribed it in 2003, and that Janssen Pharmaceuticals...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS